KLRC1 and neoplasm: Here, intratumoral delivery of NK cells along with the concomitant neutralization of the NKG2A inhibitory pathway led to strong and durable local and systemic anti‐tumor responses that were observed in syngeneic mouse tumor models and in immunodeficient mice engrafted with human HLA‐E+ tumors, which in the latter case were intratumorally treated with human NK cells.